Protagen’s leadership is responsible for the company’s continued success, innovation and partnerships. The company exists because there is a burning unmet need for people suffering from cancer and autoimmune diseases.
Our company is made up of individuals that feel they can make a difference, and meet these challenges. Today, many cancer patients receive treatments that are ineffective or even cause severe adverse effects, and many autoimmune disease patients are given treatments that are simply not right for them—Protagen wants to help end this. Contact us to find out more about how Protagen is helping to advance and improve patient management with precision diagnostic tools for immuno-oncology and autoimmune disease.
Dr Georg Lautscham, CBO
“It’s exciting to me that we are helping to develop new ways to drive the implementation of a precision medicine approach for some of the world’s most devastating diseases, both here at Protagen, and with our partners”
Georg joined Protagen in 2013, because he felt that patients suffering from cancer and autoimmune diseases should receive treatments that are both safe and effective. A chemist and immunologist by training, Georg had previously led a number of interdisciplinary teams both in Europe and the USA, and has years of experience as a biotech executive, with a strong commercial track record in business development, marketing and sales.
Dr Peter Schulz-Knappe, CSO
“A future of precision diagnostics solutions for patients suffering from autoimmune diseases and cancer means a future where people are prescribed treatments that are right for them—avoiding the incidence of harsh (and sometimes fatal) adverse effects, and helping develop therapies that are more effective” Peter joined Protagen in 2010, because he wanted to change the way in which we characterize some of the world’s most challenging diseases. An MD and cell biologist by training, Dr Schulz-Knappe has decades of management experience in R&D—gained while CEO and CSO at BioVisioN and as CSO at Proteome Sciences.
Board of directors
Dr Bernhard Kirschbaum (Chairman)
Dr. Bernhard Kirschbaum (Chairman) is an independent advisor. He was Head of Global Research and Early Development and member of the Executive Committee at Merck-Serono. Dr. Kirschbaum has a long-standing track record in pharma R&D and held various executive positions at Hoechst, Aventis, Sanofi, and Merck.
Dr Dirk H. Ehlers
Dr. Dirk H. Ehlers is President and CEO of Trumpf Medical (Hill-Rom Group). Previously he was CEO of Eppendorf AG and over the past 20 years held various senior positions within the life science industry, notably with Roche Diagnostics, Evotec, Fresenius Kabi and Olympus Diagnostics.
Dr Aristoteles Nastos
Dr. Aristoteles Nastos is Investment Manager at the NRW BANK in Dusseldorf. He has held several positions within the German life science industry, focusing on venture financing. He joined NRW bank from Peppermint Financial Partners in Berlin.
Matthias Guth is Venture Partner of MIG Funds and has been active in Venture Capital for more than 15 years. He is the Founder and Managing Director of Matthias Guth Corporate Finance GmbH. Prior to this he worked at Wellington Partners and Goetzpartners.
Oliver Schacht, PhD
Oliver Schacht, PhD is CEO of Curetis N.V. (Euronext: CURE), a molecular diagnostics company active in the area of hospital infection. He was previously CEO of Epigenomics Inc. (Seattle, USA) and CFO of epigenomics AG (Germany) and has co-founded several technology companies in Europe and the US.
Protagen is dedicated to the development of powerful diagnostic tools that aid successful therapeutic development and facilitate improved treatment strategies in the areas of autoimmune disease and immuno-oncology.
Protagen is currently setting up an international scientific advisory board with key opinion leaders from the immuno-oncology and autoimmune disease fields. These expert panels will support our efforts in engaging with the medical and scientific community to develop products that are aimed at market needs.
Protagen has a number of established and committed investors, but is always looking at entering into new partnerships to help progress its research and commercialization efforts. If you are interested in investing in the company, please contact us.
Here you will find our quarterly newsletter, “Stratified News from Dortmund”. With our newsletter we intend to regularly update you on developments at Protagen in a fresh and colorful format and we hope that you like it.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.